Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including RB-cell adult acute lymphocytic leukemia, B-cell chronic lymphocytic leukemia, B-cell neoplasm, Burkitt lymphoma, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm, viral infectious diseaseNot yet recruitingNot applicable2026-02-17NCT07412405

2 results · Page 1 of 1

Swipe the table sideways for more columns.

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
No products are listed yet.